Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia

Patrick Harrington; Katie J Doores; Deepti Radia; Amy O'Reilly; Ho Pui Jeff Lam; Jeffrey Seow; Carl Graham; Thomas Lechmere; Donal McLornan; Richard Dillon; Yogita Shanmugharaj; Andreas Espehana; Claire Woodley; Jamie Saunders; Natalia Curto-Garcia; Jennifer O'Sullivan; Kavita Raj; Shahram Kordasti; Michael H Malim; Claire Harrison; Hugues de Lavallade

doi:10.1111/bjh.17568

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia

Patrick Harrington, Katie J Doores, Deepti Radia, Amy O'Reilly, Ho Pui Jeff Lam, Jeffrey Seow, Carl Graham, Thomas Lechmere, Donal McLornan, Richard Dillon, Yogita Shanmugharaj, Andreas Espehana, Claire Woodley, Jamie Saunders, Natalia Curto-Garcia, Jennifer O'Sullivan, Kavita Raj, Shahram Kordasti, Michael H Malim, Claire HarrisonHugues de Lavallade

Research output: Contribution to journal › Article › peer-review

55 Citations (Scopus)

Abstract

Patients receiving targeted cancer treatments such as tyrosine kinase inhibitors (TKIs) have been classified in the clinically extremely vulnerable group to develop severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), including patients with chronic myeloid leukaemia (CML) taking TKIs. In addition, concerns that immunocompromised individuals with solid and haematological malignancies may not mount an adequate immune response to a single dose of SARS-CoV-2 BNT162b2 (Pfizer-BioNTech) vaccine have been raised. In the present study, we evaluated humoral and cellular immune responses after a first injection of BNT162b2 vaccine in 16 patients with CML. Seroconversion and cellular immune response before and after vaccination were assessed. By day 21 after vaccination, anti-Spike immunoglobulin G was detected in 14/16 (87·5%) of the patients with CML and all developed a neutralising antibody response [serum dilution that inhibits 50% infection (ID50 ) >50], including medium (ID50 of 200-500) or high (ID50 of 501-2000) neutralising antibodies titres in nine of the 16 (56·25%) patients. T-cell response was seen in 14/15 (93·3%) evaluable patients, with polyfunctional responses seen in 12/15 (80%) patients (polyfunctional CD4+ response nine of 15, polyfunctional CD8+ T-cell response nine of 15). These data demonstrate the immunogenicity of a single dose of SARS-CoV-2 BNT162b2 vaccine in most patients with CML, with both neutralising antibodies and polyfunctional T-cell responses seen in contrast to patients with solid tumour or lymphoid haematological malignancies.

Original language	English
Pages (from-to)	999-1006
Number of pages	8
Journal	British Journal of Haematology
Volume	194
Issue number	6
Early online date	3 Jun 2021
DOIs	https://doi.org/10.1111/bjh.17568
Publication status	Published - Sept 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/bjh.17568

Fingerprint

Dive into the research topics of 'Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia'. Together they form a unique fingerprint.

Cite this

Harrington, P., Doores, K. J., Radia, D., O'Reilly, A., Lam, H. P. J., Seow, J., Graham, C., Lechmere, T., McLornan, D., Dillon, R., Shanmugharaj, Y., Espehana, A., Woodley, C., Saunders, J., Curto-Garcia, N., O'Sullivan, J., Raj, K., Kordasti, S., Malim, M. H., ... de Lavallade, H. (2021). Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia. British Journal of Haematology, 194(6), 999-1006. https://doi.org/10.1111/bjh.17568

@article{0ff4366b3b6340c2926b02d2272cf1bd,

title = "Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia",

abstract = "Patients receiving targeted cancer treatments such as tyrosine kinase inhibitors (TKIs) have been classified in the clinically extremely vulnerable group to develop severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), including patients with chronic myeloid leukaemia (CML) taking TKIs. In addition, concerns that immunocompromised individuals with solid and haematological malignancies may not mount an adequate immune response to a single dose of SARS-CoV-2 BNT162b2 (Pfizer-BioNTech) vaccine have been raised. In the present study, we evaluated humoral and cellular immune responses after a first injection of BNT162b2 vaccine in 16 patients with CML. Seroconversion and cellular immune response before and after vaccination were assessed. By day 21 after vaccination, anti-Spike immunoglobulin G was detected in 14/16 (87·5%) of the patients with CML and all developed a neutralising antibody response [serum dilution that inhibits 50% infection (ID50 ) >50], including medium (ID50 of 200-500) or high (ID50 of 501-2000) neutralising antibodies titres in nine of the 16 (56·25%) patients. T-cell response was seen in 14/15 (93·3%) evaluable patients, with polyfunctional responses seen in 12/15 (80%) patients (polyfunctional CD4+ response nine of 15, polyfunctional CD8+ T-cell response nine of 15). These data demonstrate the immunogenicity of a single dose of SARS-CoV-2 BNT162b2 vaccine in most patients with CML, with both neutralising antibodies and polyfunctional T-cell responses seen in contrast to patients with solid tumour or lymphoid haematological malignancies.",

author = "Patrick Harrington and Doores, {Katie J} and Deepti Radia and Amy O'Reilly and Lam, {Ho Pui Jeff} and Jeffrey Seow and Carl Graham and Thomas Lechmere and Donal McLornan and Richard Dillon and Yogita Shanmugharaj and Andreas Espehana and Claire Woodley and Jamie Saunders and Natalia Curto-Garcia and Jennifer O'Sullivan and Kavita Raj and Shahram Kordasti and Malim, {Michael H} and Claire Harrison and {de Lavallade}, Hugues",

note = "Funding Information: King?s Together Rapid COVID-19 Call awards to Michael H. Malim, Katie J. Doores; A Huo Family Foundation Award to Michael H. Malim, Katie J. Doores; Chronic Disease Research Foundation award CDRF-22/2020 to Katie J. Doores, Michael H. Malim; Wellcome Trust Investigator Award 106223/Z/14/Z to Michael H. Malim; Carl Graham was supported by the MRC-KCL Doctoral Training Partnership in Biomedical Sciences (MR/N013700/1); Fondation Dormeur, Vaduz for funding equipment to Katie J. Doores. Blood Cancer UK (funding for Hugues de Lavallade); LifeArc (funding for Shahram Kordasti); Cancer Research UK (CRUK), King's Health Partners Centre (funding for Shahram Kordasti). Patrick Harrington and Hugues de Lavallade designed the research, performed the research, analysed the data and wrote the manuscript. Katie J. Doores, Jeffrey Seow, Carl Graham, Thomas Lechmere and Michael H. Malim performed the research and reviewed the manuscript. Deepti Radia, Ho Pui Jeff Lam, Richard Dillon, Claire Woodley, Jamie Saunders, Natalia Curto-Garcia, Jennifer O?Sullivan and Shahram Kordasti assisted with patient recruitment and reviewed the manuscript. Amy O?Reilly, Yogita Shanmugharaj and Andreas Espehana assisted with patient recruitment, patient interviews and reviewed the manuscript. Donal McLornan and Claire Harrison designed the research, assisted with patient recruitment and reviewed the manuscript. Funding Information: King{\textquoteright}s Together Rapid COVID‐19 Call awards to Michael H. Malim, Katie J. Doores; A Huo Family Foundation Award to Michael H. Malim, Katie J. Doores; Chronic Disease Research Foundation award CDRF‐22/2020 to Katie J. Doores, Michael H. Malim; Wellcome Trust Investigator Award 106223/Z/14/Z to Michael H. Malim; Carl Graham was supported by the MRC‐KCL Doctoral Training Partnership in Biomedical Sciences (MR/N013700/1); Fondation Dormeur, Vaduz for funding equipment to Katie J. Doores. Blood Cancer UK (funding for Hugues de Lavallade); LifeArc (funding for Shahram Kordasti); Cancer Research UK (CRUK), King's Health Partners Centre (funding for Shahram Kordasti). Publisher Copyright: {\textcopyright} 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = sep,

doi = "10.1111/bjh.17568",

language = "English",

volume = "194",

pages = "999--1006",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "6",

}

Harrington, P , Doores, KJ, Radia, D, O'Reilly, A, Lam, HPJ, Seow, J , Graham, C , Lechmere, T , McLornan, D , Dillon, R, Shanmugharaj, Y, Espehana, A, Woodley, C, Saunders, J, Curto-Garcia, N, O'Sullivan, J, Raj, K, Kordasti, S , Malim, MH , Harrison, C & de Lavallade, H 2021, 'Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia', British Journal of Haematology, vol. 194, no. 6, pp. 999-1006. https://doi.org/10.1111/bjh.17568

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia. / Harrington, Patrick ; Doores, Katie J; Radia, Deepti et al.
In: British Journal of Haematology, Vol. 194, No. 6, 09.2021, p. 999-1006.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia

AU - Harrington, Patrick

AU - Doores, Katie J

AU - Radia, Deepti

AU - O'Reilly, Amy

AU - Lam, Ho Pui Jeff

AU - Seow, Jeffrey

AU - Graham, Carl

AU - Lechmere, Thomas

AU - McLornan, Donal

AU - Dillon, Richard

AU - Shanmugharaj, Yogita

AU - Espehana, Andreas

AU - Woodley, Claire

AU - Saunders, Jamie

AU - Curto-Garcia, Natalia

AU - O'Sullivan, Jennifer

AU - Raj, Kavita

AU - Kordasti, Shahram

AU - Malim, Michael H

AU - Harrison, Claire

AU - de Lavallade, Hugues

N1 - Funding Information: King?s Together Rapid COVID-19 Call awards to Michael H. Malim, Katie J. Doores; A Huo Family Foundation Award to Michael H. Malim, Katie J. Doores; Chronic Disease Research Foundation award CDRF-22/2020 to Katie J. Doores, Michael H. Malim; Wellcome Trust Investigator Award 106223/Z/14/Z to Michael H. Malim; Carl Graham was supported by the MRC-KCL Doctoral Training Partnership in Biomedical Sciences (MR/N013700/1); Fondation Dormeur, Vaduz for funding equipment to Katie J. Doores. Blood Cancer UK (funding for Hugues de Lavallade); LifeArc (funding for Shahram Kordasti); Cancer Research UK (CRUK), King's Health Partners Centre (funding for Shahram Kordasti). Patrick Harrington and Hugues de Lavallade designed the research, performed the research, analysed the data and wrote the manuscript. Katie J. Doores, Jeffrey Seow, Carl Graham, Thomas Lechmere and Michael H. Malim performed the research and reviewed the manuscript. Deepti Radia, Ho Pui Jeff Lam, Richard Dillon, Claire Woodley, Jamie Saunders, Natalia Curto-Garcia, Jennifer O?Sullivan and Shahram Kordasti assisted with patient recruitment and reviewed the manuscript. Amy O?Reilly, Yogita Shanmugharaj and Andreas Espehana assisted with patient recruitment, patient interviews and reviewed the manuscript. Donal McLornan and Claire Harrison designed the research, assisted with patient recruitment and reviewed the manuscript. Funding Information: King’s Together Rapid COVID‐19 Call awards to Michael H. Malim, Katie J. Doores; A Huo Family Foundation Award to Michael H. Malim, Katie J. Doores; Chronic Disease Research Foundation award CDRF‐22/2020 to Katie J. Doores, Michael H. Malim; Wellcome Trust Investigator Award 106223/Z/14/Z to Michael H. Malim; Carl Graham was supported by the MRC‐KCL Doctoral Training Partnership in Biomedical Sciences (MR/N013700/1); Fondation Dormeur, Vaduz for funding equipment to Katie J. Doores. Blood Cancer UK (funding for Hugues de Lavallade); LifeArc (funding for Shahram Kordasti); Cancer Research UK (CRUK), King's Health Partners Centre (funding for Shahram Kordasti). Publisher Copyright: © 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/9

Y1 - 2021/9

N2 - Patients receiving targeted cancer treatments such as tyrosine kinase inhibitors (TKIs) have been classified in the clinically extremely vulnerable group to develop severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), including patients with chronic myeloid leukaemia (CML) taking TKIs. In addition, concerns that immunocompromised individuals with solid and haematological malignancies may not mount an adequate immune response to a single dose of SARS-CoV-2 BNT162b2 (Pfizer-BioNTech) vaccine have been raised. In the present study, we evaluated humoral and cellular immune responses after a first injection of BNT162b2 vaccine in 16 patients with CML. Seroconversion and cellular immune response before and after vaccination were assessed. By day 21 after vaccination, anti-Spike immunoglobulin G was detected in 14/16 (87·5%) of the patients with CML and all developed a neutralising antibody response [serum dilution that inhibits 50% infection (ID50 ) >50], including medium (ID50 of 200-500) or high (ID50 of 501-2000) neutralising antibodies titres in nine of the 16 (56·25%) patients. T-cell response was seen in 14/15 (93·3%) evaluable patients, with polyfunctional responses seen in 12/15 (80%) patients (polyfunctional CD4+ response nine of 15, polyfunctional CD8+ T-cell response nine of 15). These data demonstrate the immunogenicity of a single dose of SARS-CoV-2 BNT162b2 vaccine in most patients with CML, with both neutralising antibodies and polyfunctional T-cell responses seen in contrast to patients with solid tumour or lymphoid haematological malignancies.

AB - Patients receiving targeted cancer treatments such as tyrosine kinase inhibitors (TKIs) have been classified in the clinically extremely vulnerable group to develop severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), including patients with chronic myeloid leukaemia (CML) taking TKIs. In addition, concerns that immunocompromised individuals with solid and haematological malignancies may not mount an adequate immune response to a single dose of SARS-CoV-2 BNT162b2 (Pfizer-BioNTech) vaccine have been raised. In the present study, we evaluated humoral and cellular immune responses after a first injection of BNT162b2 vaccine in 16 patients with CML. Seroconversion and cellular immune response before and after vaccination were assessed. By day 21 after vaccination, anti-Spike immunoglobulin G was detected in 14/16 (87·5%) of the patients with CML and all developed a neutralising antibody response [serum dilution that inhibits 50% infection (ID50 ) >50], including medium (ID50 of 200-500) or high (ID50 of 501-2000) neutralising antibodies titres in nine of the 16 (56·25%) patients. T-cell response was seen in 14/15 (93·3%) evaluable patients, with polyfunctional responses seen in 12/15 (80%) patients (polyfunctional CD4+ response nine of 15, polyfunctional CD8+ T-cell response nine of 15). These data demonstrate the immunogenicity of a single dose of SARS-CoV-2 BNT162b2 vaccine in most patients with CML, with both neutralising antibodies and polyfunctional T-cell responses seen in contrast to patients with solid tumour or lymphoid haematological malignancies.

UR - http://www.scopus.com/inward/record.url?scp=85107144328&partnerID=8YFLogxK

U2 - 10.1111/bjh.17568

DO - 10.1111/bjh.17568

M3 - Article

C2 - 34085278

SN - 0007-1048

VL - 194

SP - 999

EP - 1006

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 6

ER -

Harrington P , Doores KJ, Radia D, O'Reilly A, Lam HPJ, Seow J et al. Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia. British Journal of Haematology. 2021 Sept;194(6):999-1006. Epub 2021 Jun 3. doi: 10.1111/bjh.17568

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this